Short Report
Hero Background

Cut through the noise.
Trade on the signal.

A weekly synthesis of institutional-grade financial reports and market mechanics.

No spam. Unsubscribe anytime.

All Reports

Filters

Companies

Tickers

Authors

Latest Reports

Author: White Diamond Research Ticker: PLSE

Evidence Reveals Pulse Biosciences Is A Joke – It’s Years Late To The Pulsed Field Ablation Market And Its “Nanosecond” Technology Is Impractical And Not Novel – $1 Price Target

Pulse Biosciences (PLSE) faces critical challenges in cardiac ablation technology, burning $15M quarterly with minimal revenue, unproven nsPFA technology, and significant bankruptcy risks in competitive medical device market

Aug 24, 2023 3 min read
Author: Capybara Research Ticker: KSCP

More Problems at Knightscope - A Supplemental Report

Knightscope (KSCP) financial analysis reveals critical insolvency risks: extreme share dilution, negative margins, minimal robot revenue, auditor concerns, and potential bankruptcy threatening investor capital

Aug 19, 2023 3 min read
Author: Capybara Research Ticker: KSCP

Knightscope: An Unprofitable Company With a Flawed Product, High Cash Burn, and Inevitable Dilution

Knightscope (KSCP) stock analysis reveals cash-burning security robot company with failed deployments, high costs, and imminent shareholder dilution. Critical research exposes operational risks and financial instability in emerging tech sector

Jul 16, 2023 3 min read
Author: Fuzzy Panda Research Ticker: XPOF

Xponential Fitness (XPOF) – “Abusive Franchisor That Is A House Of Cards”

Exposing Xponential Fitness (XPOF) fraud: CEO's questionable past, franchisee losses, manipulated metrics, potential debt crisis, and systematic financial misrepresentation in boutique fitness industry

Jun 27, 2023 3 min read
Author: White Diamond Research Ticker: RPMT

Rego Payment Architectures has A Weak Product, Recently Added Debt And Significant Dilution – 25c 1-Year Price Target

White Diamond Research exposes Rego Payment Architectures (RPMT) with a 75% downside risk, highlighting Mazoola's failed product, mounting $20M debt, minimal revenue, and potential stock dilution in the competitive fintech market

May 11, 2023 3 min read
Author: Fuzzy Panda Research Ticker: LCID

Sell Lucid – We Believe Buyout Rumor is FAKE NEWS – Came Right After Lock-up Expiration

Fuzzy Panda Research exposes Lucid Group (LCID) stock manipulation through false Saudi PIF buyout rumor, revealing negative margins, poor delivery rates, and potential market deception in electric vehicle sector

Jan 29, 2023 3 min read
Author: White Diamond Research Ticker: USBC

Know Labs Is An Obvious Medical Device Scam, We’re Calling: “Theranos’ Retarded Cousin”

White Diamond Research exposes Know Labs (KNW) as a potential medical device scam, revealing zero revenue, unproven glucose monitoring technology, massive share dilution, and lack of scientific validation in devastating short-seller report

Dec 22, 2022 3 min read
Author: Fuzzy Panda Research Company: Fisker (Private)

Fisker – Undisclosed Bank Guarantees Show the Cash is Pledged; Fisker’s History of Lies Revealed

Fisker Inc. exposed: EV maker faces critical financial challenges, alleged deception by CEO Henrik Fisker, hidden bank guarantees, and potential regulatory risks in electric vehicle production and startup governance

Dec 1, 2022 3 min read
sabizabulin Author: White Diamond Research

Part 2: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely

White Diamond Research exposes critical flaws in Veru's COVID-19 drug trial, revealing data integrity issues, methodological problems, and potential FDA rejection risks for sabizabulin treatment

Jul 26, 2022 3 min read
VERU Author: White Diamond Research

Part 1: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely

Veru's Sabizabulin COVID-19 drug faces potential FDA rejection due to critical Phase 3 trial design flaws, small sample size, patient selection issues, and questionable mortality data suggesting ineffective treatment

Jul 18, 2022 3 min read
Author: Bonitas Research Ticker: ATEC

Short Alphatec (Nasdaq: ATEC)

Bonitas Research exposes Alphatec Holdings (ATEC) alleged revenue inflation scheme, undisclosed FDA recalls, suspicious related-party distributors, insider selling, and financial irregularities threatening investor confidence

Jul 14, 2022 3 min read
Author: Bonitas Research Ticker: GGR

Short Gogoro (Nasdaq: GGR)

Gogoro's electric scooter sales plummet 20% in Q2 2022, market share erodes as KYMCO challenges battery-swapping dominance, with declining registrations, compressed margins, and poor app ratings threatening growth

Jul 12, 2022 3 min read

The Signal. No Noise.

Join 50,000+ investors receiving our weekly synthesis.